Sirolimus inhibits the growth and metastatic progression of hepatocellular carcinoma
- 296 Downloads
Immunosuppressive therapy after liver transplantation for hepatocellular carcinoma (HCC) is one of the major contributory factors for HCC recurrence and metastasis. Sirolimus, a potent immunosuppressant, has been reported to be an effective inhibitor in a variety of tumors. The present study is designed to explore whether sirolimus could block the growth and metastatic progression of HCC.
MHCC97H cells were used as targets to explore the effect of sirolimus on cell cycle progression, apoptosis, proliferation, and its antiangiogenic mechanism. LCI-D20, a highly metastatic model of human HCC in nude mice, was also used as the model tumor to explore the effect of sirolimus on tumor growth and metastatic progression.
In vitro, sirolimus induced cell cycle arrest at the G1 checkpoint and blocked proliferation of MHCC97H cells but did not induce apoptosis. In vivo, sirolimus prevented tumor growth and metastatic progression in LCI-D20. Intratumoral microvessel density and circulating levels of VEGF in tumor-bearing mice were also significantly reduced in sirolimus treatment group. Quantitative RT-PCR showed that sirolimus down-regulated the mRNA expression of VEGF and HIF-1a, but not of bFGF, and TGF-b in MHCC97H cells. Furthermore, western blot analysis confirmed that sirolimus also decreased expression of HIF-1a at protein level, in parallel with the down-regulation of the levels of VEGF protein excretion in a time-dependent manner as compared to untreated control cells following anoxia.
The immunosuppressive macrolide sirolimus prevents the growth and metastatic progression of HCC, and suppresses VEGF synthesis and secretion by downregulating HIF-1a expression. Sirolimus may be useful for clinical application in patients who received a liver transplant for HCC.
KeywordsSirolimus Hepatocellular carcinoma Liver transplantation VEGF HIF-1 a protein Immunosuppression Neoplasm metastasis
The research was supported by grants from the Hi-tech Research and Development Program of China (2007AA02Z479), and the National Natural Science Foundation Grant of China (30700815).
- Blancher C, Moore JW, Robertson N, Harris AL (2001) Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxiainducible factor (HIF)-1 alpha, HIF-2 alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3′-kinase/Akt signaling pathway. Cancer Res 61:7349–7355PubMedGoogle Scholar
- Chan S, Scheulen ME, Johnston S, Mross K, Cardoso F, Dittrich C et al (2005) Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 23:5314–5322. doi: 10.1200/JCO.2005.66.130 PubMedCrossRefGoogle Scholar
- Clarke K, Smith K, Gullick WJ, Harris AL (2001) Mutant epidermal growth factor receptor enhances induction of vascular endothelial growth factor by hypoxia and insulin-like growth factor-1 via a PI3 kinase dependent pathway. Br J Cancer 84:1322–1399. doi: 10.1054/bjoc.2001.1805 PubMedCrossRefGoogle Scholar
- Hale DA, Gottschalk R, Fukuzaki T, Wood ML, Maki T, Monaco AP (1997) Superiority of sirolimus (rapamycin) over cyclosporine in augmenting allograft and xenograft survival in mice treated with antilymphocyte serum and donor-specific bone marrow. Transplantation 63:359–364. doi: 10.1097/00007890-199702150-00005 PubMedCrossRefGoogle Scholar
- Jain RK, Safabakhsh N, Sckell A, Chen Y, Jiang P, Benjamin L et al (1998) Endothelial cell death, angiogenesis, and microvascular function after castration in an androgendependent tumor: role of vascular endothelial growth factor. Proc Natl Acad Sci USA 95:10820–10825. doi: 10.1073/pnas.95.18.10820 PubMedCrossRefGoogle Scholar
- Sun FX, Tang ZY, Liu KD, Xue Q, Gao DM, Yu YQ et al (1996) Establishment of a metastatic model of human hepatocellular carcinoma in nude mice via orthotopic implantation of histologically intact tissues. Int J Cancer 66:239–243. doi:10.1002/(SICI)1097-0215(19960410)66:2<239::AID-IJC17>3.0.CO;2-7PubMedCrossRefGoogle Scholar